Kenvue stock extends slide as analysts stay neutral
Published on 09/10/2026 at 12:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Kenvue stock (ISIN US49177J1025) closed at USD 17.75 on its primary U.S. exchange on September 9, 2026, down 3.5 percent from the previous session and sitting toward the middle of its 52-week range between USD 14.02 and USD 20.13, according to data cited by GuruFocus.
Share price under pressure in recent trading
On September 9, 2026, Kenvue shares fell 3.5 percent to a closing price of USD 17.75, marking a notable single-session decline that contrasts with the stock’s relatively stable performance over the broader year.GuruFocus reports that the 52-week trading range for Kenvue currently spans from a low of USD 14.02 to a high of USD 20.13, giving investors a sense of the volatility the stock has experienced over the past year.
Relative to an estimated fair value of USD 19.74, Kenvue’s closing level of USD 17.75 on September 9, 2026 implies a discount of approximately 10.1 percent, suggesting that the stock trades below one widely used intrinsic value estimate.GuruFocus For investors, this combination of a recent price setback and a valuation discount raises the question of whether the market is underappreciating Kenvue’s earnings profile or signaling skepticism about future growth.
Recent quarterly figures show modest growth
Fundamentally, Kenvue’s most recently reported interim numbers point to modest top-line expansion and slightly improving earnings power. According to a summary of its fiscal second-quarter 2026 results,StockTitan Kenvue generated net sales of USD 3.96 billion in fiscal Q2 2026, representing growth of 3.0 percent year over year, including 1.6 percent organic sales growth and a 1.4 percent foreign-currency benefit. That comparison shows that reported revenue has increased by roughly USD 115 million versus the prior-year quarter, assuming a similar base level of around USD 3.85 billion.
The same second-quarter 2026 data set indicates that Kenvue’s gross profit margin stood at 58.2 percent, with an adjusted gross margin of 60.2 percent, while operating income margin was 17.7 percent and the adjusted operating margin reached 22.1 percent.StockTitan These figures reflect slightly lower margins compared with the prior-year period, highlighting that while revenue is growing, profitability has come under mild pressure, likely due to input-cost dynamics, promotional spending or mix effects. For shareholders, the key point is that the company is still posting healthy double-digit operating margins, but the incremental margin compression may limit how quickly earnings can expand.
From a longer-term perspective, the combination of mid-single-digit revenue growth and robust but easing margins sets up a balanced picture: Kenvue is not a high-growth story, yet its brand portfolio and margin structure give it capacity to generate solid cash flows. Investors monitoring the stock will therefore pay close attention to whether upcoming quarters show a stabilization or improvement in gross and operating margins compared with fiscal year 2025, as that trend will be critical for sustaining any rerating closer to the fair-value estimates mentioned above.
Analyst consensus remains cautious with limited upside
Despite the valuation discount indicated by the GF Value framework, the analyst community currently takes a neutral stance on Kenvue stock. According to an overview of institutional positioning and analyst commentary,MarketBeat three analysts currently rate Kenvue as a Buy, while twelve assign a Hold rating. That distribution yields a consensus rating of Hold and an average price target of USD 19.27, implying roughly 8.5 percent upside from the September 9, 2026 closing price of USD 17.75.
Additional data on individual price targets underscores this cautious tone. In a recent compilation of analyst actions on the stock,QuiverQuant three analysts are listed with one-year targets clustered tightly around the current consensus: Filippo Falorni at Citigroup set a price objective of USD 19.00 on April 15, 2026, Lauren Lieberman at Barclays reiterated a target of USD 18.00 on April 14, 2026, and Peter Grom at UBS also defined an USD 18.00 target on April 7, 2026. Taken together, these calls outline an expected trading band just modestly above the recent price, rather than a dramatic rerating story.
The cautious stance is reinforced by incremental commentary from other outlets. A recent markets overview notes that RBC Capital and Barclays both stick to Hold ratings on Kenvue, emphasizing that Wall Street analysts are broadly neutral on the stock and see only measured upside from current levels.The Globe and Mail For investors, this backdrop means that while the shares appear undervalued by some quantitative metrics, sentiment in the research community remains restrained, with limited conviction about near-term catalysts that could push the price decisively higher.
Stock level and valuation as of the latest close
At the most recent completed U.S. trading session on September 9, 2026, Kenvue stock closed at USD 17.75 on its primary exchange in the United States, 3.5 percent below the prior day’s close and around 11.8 percent below the 52-week high of USD 20.13, while remaining 26.6 percent above the 52-week low of USD 14.02, all in USD terms. As of early September 2026, publicly available market data place Kenvue’s market capitalization at approximately USD 35.52 billion, positioning it among the larger global consumer-health names by equity value.CompaniesMarketCap For shareholders, the current setup combines a sizeable, stable franchise with a share price that has recently weakened, against a backdrop of modest revenue growth and neutral analyst sentiment.
Kenvue stock key data
- Company: Kenvue Inc.
- ISIN: US49177J1025
- Ticker: KVUE
- Trading venue: NYSE
- Price (as of September 9, 2026): 17.75 USD
- Market capitalization: 35.52 billion USD (as of September 2026)
- Sector / Industry: Consumer healthcare
- Index membership: S&P 500
